Eintrag weiter verarbeiten
Venous thromboembolism and women's health
Gespeichert in:
Personen und Körperschaften: | , , , |
---|---|
Titel: |
Venous thromboembolism and women's health |
In: | British Journal of Haematology, 183, 2018, 3, S. 346-363 |
veröffentlicht: |
Wiley
|
Umfang: | 346-363 |
ISSN: |
0007-1048 1365-2141 |
DOI: | 10.1111/bjh.15608 |
Zusammenfassung: | <jats:title>Summary</jats:title><jats:p>The prevention and treatment of venous thromboembolism (<jats:styled-content style="fixed-case">VTE</jats:styled-content>) poses distinct gender‐specific challenges. Women of childbearing age are at an increased risk of <jats:styled-content style="fixed-case">VTE</jats:styled-content> secondary to the transient risk factors of combined hormonal contraception (<jats:styled-content style="fixed-case">CHC</jats:styled-content>) and pregnancy. Cancers specific to women are associated with a significant burden of <jats:styled-content style="fixed-case">VTE</jats:styled-content>; whilst the incidence of <jats:styled-content style="fixed-case">VTE</jats:styled-content> in localised breast cancer is 5 per 1000 person‐years, more cases are seen due to the prevalence of breast cancer. Treatment of <jats:styled-content style="fixed-case">VTE</jats:styled-content> in women can be complicated by abnormal uterine bleeding, now increasingly reported with direct oral anticoagulants (<jats:styled-content style="fixed-case">DOAC</jats:styled-content>s) as well as vitamin K antagonists. Divergence between international guidelines regarding the use of <jats:styled-content style="fixed-case">CHC</jats:styled-content> following an oestrogen‐associated <jats:styled-content style="fixed-case">VTE</jats:styled-content> and appropriate withdrawal of such contraception requires clarification for clinicians. Additionally, there is uncertainty as to whether to consider such events provoked or unprovoked and, consequently, the optimal duration of treatment in these women remains unclear. During pregnancy and the puerperium, the traditional anticoagulants remain the agents of choice with no further advances in <jats:styled-content style="fixed-case">DOAC</jats:styled-content> safety data, and similarly in lactation. Further studies evaluating the safety and optimal treatment strategies in these women are awaited.</jats:p> |
Format: | E-Article |
Quelle: | Wiley (CrossRef) |
Sprache: | Englisch |